Viking Therapeutics, Inc. - Common Stock (VKTX)
38.08
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 3rd, 5:23 AM EST
Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.
Via The Motley Fool · November 3, 2025
Viking's stock surged in one trading session after a positive clinical trial report last year.
Via The Motley Fool · November 2, 2025
These stocks may be down as of late, but investors shouldn't count them out in the long run.
Via The Motley Fool · October 31, 2025
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.
Via Stocktwits · October 31, 2025
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metserastocktwits.com
Via Stocktwits · October 30, 2025
Viking Therapeutics Ignites Retail-Trader Frenzy Amid Deal Speculation, Upcoming Trial Catalystsstocktwits.com
Via Stocktwits · October 6, 2025
The company had positive updates on its clinical trials.
Via The Motley Fool · October 23, 2025
Viking Therapeutics shares are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.
Via Benzinga · October 23, 2025
Morgan Stanley raised its price target on VKTX to $102 from $98 while maintaining an ‘Overweight’ rating.
Via Stocktwits · October 23, 2025
Viking Therapeutics stock popped Thursday on the lightening pace it's enrolling patients in a pair of obesity treatment tests.
Via Investor's Business Daily · October 23, 2025
Viking Therapeutics Q3 2025 results show an earnings miss, with shares falling. The company's key Phase 3 obesity trial remains on track.
Via Chartmill · October 22, 2025
Retail investors prepare for the first busy week in the Q3 earnings season, with Tesla, Netflix and Intel on deck.
Via Benzinga · October 20, 2025
These companies are jockeying for position in a potential $150 billion market opportunity.
Via The Motley Fool · October 20, 2025
These stocks have climbed in the triple digits over the past few years.
Via The Motley Fool · October 17, 2025
The smaller drugmaker is looking to disrupt a fast-growing market.
Via The Motley Fool · October 16, 2025
The company is readying to take on pharma giants Novo Nordisk and Eli Lilly.
Via The Motley Fool · October 13, 2025
As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.
Via The Motley Fool · October 12, 2025
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
Via The Motley Fool · October 9, 2025
Buying these three stocks offers you instant diversification.
Via The Motley Fool · October 5, 2025
There's more to this company than its performance on the stock market this year suggests.
Via The Motley Fool · September 30, 2025
Investors once speculated that Pfizer might consider acquiring Viking.
Via The Motley Fool · September 25, 2025